BIOPURE CORP
10-Q, EX-27.2, 2000-09-12
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: BIOPURE CORP, 10-Q, EX-27.1, 2000-09-12
Next: THORNBURG INVESTMENT TRUST, 13F-HR/A, 2000-09-12



<TABLE> <S> <C>

<ARTICLE> 5
<CURRENCY> U.S. DOLLAR

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          OCT-31-2000
<PERIOD-START>                             APR-30-2000
<PERIOD-END>                               JUL-29-2000
<EXCHANGE-RATE>                                      1
<CASH>                                          95,616
<SECURITIES>                                         0
<RECEIVABLES>                                      421
<ALLOWANCES>                                        40
<INVENTORY>                                      3,089
<CURRENT-ASSETS>                               103,149
<PP&E>                                          44,265
<DEPRECIATION>                                  19,867
<TOTAL-ASSETS>                                 127,880
<CURRENT-LIABILITIES>                           12,717
<BONDS>                                              0
                                0
                                          0
<COMMON>                                           249
<OTHER-SE>                                     113,146
<TOTAL-LIABILITY-AND-EQUITY>                   127,880
<SALES>                                            836
<TOTAL-REVENUES>                                   836
<CGS>                                            1,215
<TOTAL-COSTS>                                    1,215
<OTHER-EXPENSES>                                 6,229<F1>
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  17
<INCOME-PRETAX>                                (7,191)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (7,191)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (7,191)
<EPS-BASIC>                                     (0.29)
<EPS-DILUTED>                                        0

<FN>
<F1>OTHER EXPENSES ARE FOR R&D INCURRED IN DEVELOPING PRODUCT FOR MARKET.
</FN>



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission